Tissue Regenix Group Plc Market Cap ($628.37)
Market Cap & Net Worth: Tissue Regenix Group Plc (TRX)
Tissue Regenix Group Plc market cap. Tissue Regenix Group Plc (LSE:TRX) has a market capitalization of $628.37 (GBX5.16 Million) as of November 8, 2026. Listed on the LSE stock exchange, this UK-based company holds position #32025 globally and #1321 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Tissue Regenix Group Plc's stock price GBX0.07 by its total outstanding shares 71234507 (71.23 Million). Also see Tissue Regenix Group Plc cash conversion from operations for how efficiently the company converts equity into cash flow.
Tissue Regenix Group Plc Market Cap History (2015–2025)
Tissue Regenix Group Plc market cap history from 2015 to 2025. Data shows change from $13.22 Million to $628.37 (-62.66% CAGR). Check TRX live share price for real-time trading data and today's change.
Index Memberships
Tissue Regenix Group Plc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE AIM All Share Index
FTAI
|
$990.01 Million | 0.00% | #480 of 722 |
Weight: Tissue Regenix Group Plc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Tissue Regenix Group Plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Tissue Regenix Group Plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore TRX year-over-year net asset growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.02x
Tissue Regenix Group Plc's market cap is 0.02 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $17.77 Million | $1.57 Million | -$10.68 Million | 11.29x | N/A |
| 2017 | $8.02 Million | $5.23 Million | -$9.22 Million | 1.53x | N/A |
| 2018 | $5.63 Million | $11.62 Million | -$8.19 Million | 0.48x | N/A |
| 2018 | $5.63 Million | $5.23 Million | -$9.22 Million | 1.08x | N/A |
| 2019 | $866.72K | $13.03 Million | -$6.97 Million | 0.07x | N/A |
| 2020 | $468.03K | $12.83 Million | -$9.71 Million | 0.04x | N/A |
| 2021 | $463.69K | $19.75 Million | -$4.79 Million | 0.02x | N/A |
| 2022 | $489.70K | $24.48 Million | -$2.69 Million | 0.02x | N/A |
| 2023 | $450.69K | $29.49 Million | -$1.71 Million | 0.02x | N/A |
| 2024 | $520.03K | $28.65 Million | -$713.00K | 0.02x | N/A |
Competitor Companies of TRX by Market Capitalization
Companies near Tissue Regenix Group Plc in the global market cap rankings as of November 8, 2026. Also see Tissue Regenix Group Plc assets under control for a full breakdown of the balance sheet.
Key companies related to Tissue Regenix Group Plc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Tissue Regenix Group Plc (2015–2025)
Market capitalization of Tissue Regenix Group Plc from 2015 to today. Between 2015 and today, Tissue Regenix Group Plc's market cap moved from $13.22 Million to $ 628.37, with a yearly change of -62.66%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | GBX628.37 | -99.88% |
| 2024 | GBX520.03K | +15.38% |
| 2023 | GBX450.69K | -7.96% |
| 2022 | GBX489.70K | +5.61% |
| 2021 | GBX463.69K | -0.93% |
| 2020 | GBX468.03K | -46.00% |
| 2019 | GBX866.72K | -84.62% |
| 2018 | GBX5.63 Million | -29.73% |
| 2017 | GBX8.02 Million | -54.88% |
| 2016 | GBX17.77 Million | +34.43% |
| 2015 | GBX13.22 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Tissue Regenix Group Plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $628.37 USD |
| MoneyControl | $628.37 USD |
| MarketWatch | $628.37 USD |
| marketcap.company | $628.37 USD |
| Reuters | $628.37 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Tissue Regenix Group Plc
Tissue Regenix Group plc, a medical technology company, develops and commercializes platform technologies for bone graft substitutes, skin, and soft tissue biologics markets in the United States and internationally. The company operates in two segments, dCELL and BioRinse. It offers dCELL technology, a soft tissue decellularisation process that removes DNA and other cellular material from animal … Read more